The performance of companies tied Pharma to iconic drugs like Viagra presents a complex investment scenario . While the initial rise of copyright, fueled by Viagra's remarkable popularity, generated substantial profits , the loss of exclusivity in key regions has introduced substantial risk . Investors are now facing the consequences of rival medic